A clearer understanding of the mechanisms that contribute to trastuzumab resistance is needed in order to develop new therapeutic strategies, and, ultimately, to improve survival outcomes for patients with HER2-over-expressing breast cancer. Here, ERBB2 is linked to breast cancer.